Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31194453 | 1.00 | BCKDK (0.50) | BCKDKMCL1RXFP1BCL2L1MGLL | |
| SCHEMBL868993 | 0.88 | BCKDK (0.66) | BCKDKMCL1RXFP1BCL2L1MGLL | |
| SCHEMBL120426 | 0.85 | ESR1 (0.43) | BCKDKMCL1RXFP1MGLLF10 | |
| SCHEMBL6840329 | 0.84 | MEN1 (0.40) | BCKDKMCL1BCL2L1MGLLRAB9A | |
| SCHEMBL692750 | 0.80 | CSNK1D (0.41) | RXFP1TSHRPRNPMAPK1PPARG | |
| SCHEMBL28836579 | 0.80 | LMNA (0.48) | BCKDKMCL1RXFP1BCL2L1TSHR | |
| SCHEMBL30099150 | 0.80 | LMNA (0.48) | BCKDKMCL1RXFP1BCL2L1TSHR | |
| SCHEMBL2279755 | 0.80 | BCKDK (0.77) | BCKDKMCL1RXFP1BCL2L1TSHR | |
| SCHEMBL2723054 | 0.79 | BCKDK (0.75) | BCKDKMCL1RXFP1BCL2L1TSHR | |
| SCHEMBL5023231 | 0.76 | MCL1 (0.77) | BCKDKMCL1RXFP1BCL2L1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115023426-A | Pesticidally active heterocyclic derivatives with sulfur-containing substituents | 先正达农作物保护股份公司 | 2022-09-06 | — | — | CN | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9375430-B2 | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-28 | — | — | US | disclosed |
| US-9375430-B2 | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-28 | — | — | US | disclosed |
| EP-2760451-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | Janssen Pharmaceutica N.V. (BE) | 2014-08-06 | — | — | EP | disclosed |
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| EP-2621918-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130085130-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085130-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049293-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049293-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012099785-A2 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012044613-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044613-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, PNLIP, LIPA | BCKDK 791/4885MCL1 3086/4885RXFP1 2280/4885 |
| US-20130085130-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | PNLIP, LIPC, LPL | BCKDK 392/4885MCL1 3827/4885RXFP1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.